1. A balancing device for turbocompressors comprising a base structure which supports elastically a supporting structure which has a flange for supporting a receptacle of a rotating element, the balancing device further comprising the rotating element, said rotating element being movable with a rotary motion about its own rotation axis, the balancing device further comprising actuation means adapted to actuate lever means along a substantially radial direction, said lever means being adapted to generate a force for fixing said receptacle to said flange in a direction which is substantially parallel to said rotation axis.
2. The balancing device according to claim 1, wherein elastic elements are disposed between said actuation means and said lever means, the elastic elements being elastic in a substantially radial direction and are adapted to uncouple mechanically said actuation means from said lever means.
3. The balancing device according to claim 2, wherein in said lever means a power arm to which the force of said actuation means is applied, in said substantially radial direction, is longer than a resistance arm that generates the force for fixing in said direction which is substantially parallel to said rotation axis.
4. The balancing device according to claim 1, wherein said lever means are adapted to perform a translational movement in a radial direction and to rotate on a plane that passes through said rotation axis.
5. The balancing device according to claim 4, wherein said supporting structure comprises a portion which forms a substantially elliptical slot, said lever means comprising a pivot which engages said slot to allow said translation and said rotation of said lever means.
6. The balancing device according to claim 1, further comprising retention means which are interposed between said actuation means and said lever means and are adapted to delay rotation of said lever means.
7. The balancing device according to claim 6, wherein said retention means are comprised between a protrusion of said lever means which is directed radially toward said actuation means and the actuation means themselves.
8. The balancing device according to claim 1, wherein said actuation means are mounted in pairs arranged on the same diameter.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound having the formula:
or a physiologically acceptable salt thereof, wherein R1 is a halogen.
2. The compound of claim 1 wherein R1 is selected from the group consisting of chloro, fluoro and bromo.
3. The compound of claim 2 wherein R1 is chloro.
4. A pharmaceutical composition comprising the compound of claim 1 and a physiologically acceptable carrier or excipient.
5. A compound having the structure:
or a physiologically acceptable salt thereof, wherein R1 is a halogen.
6. The compound of claim 5 wherein R1 is selected from the group consisting of chloro, fluoro and bromo.
7. The compound of claim 6 wherein R1 is chloro.
8. A pharmaceutical composition comprising the compound of claim 5 and a physiologically acceptable carrier or excipient.
9. A method of treating a disease selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemiareperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
10. A compound having the formula:
or a physiologically acceptable salt thereof, wherein R1 is a halogen.
11. A pharmaceutical composition comprising the compound of claim 10 and a physiologically acceptable carrier or excipient.
12. The compound of claim 10 wherein R1 is selected from the group consisting of chloro, fluoro and bromo.
13. The compound of claim 12 wherein R1 is chloro.
14. A method of treating a disease selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemiareperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
15. A method of treating a disease selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemiareperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
16. A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
17. The method of claim 16, wherein said inflammatory disease is an acute inflammatory disease.
18. The method of claim 16, wherein said inflammatory disease is a chronic inflammatory disease.
19. A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
20. The method of claim 19, wherein said inflammatory disease is an acute inflammatory disease.
21. The method of claim 19, wherein said inflammatory disease is a chronic inflammatory disease.
22. A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
23. The method of claim 22 wherein said inflammatory disease is an acute inflammatory disease.
24. The method of claim 22 wherein said inflammatory disease is a chronic inflammatory disease.
25. A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
26. The method of claim 25 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter’s syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
27. A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
28. The method of claim 27 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter’s syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
29. A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
30. The method of claim 29 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter’s syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
31. A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
32. The method of claim 31 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
33. The method of claim 32 wherein said acute inflammatory demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
34. The method of claim 31 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
35. The method of claim 34 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
36. A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
37. The method of claim 36 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
38. The method of claim 37 wherein said acute inflammatory demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
39. The method of claim 36 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
40. The method of claim 39 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
41. A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
42. The method of claim 41 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
43. The method of claim 42 wherein said acute inflammatory demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
44. The method of claim 41 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
45. The method of claim 44 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
46. A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
47. A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
48. A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.
49. A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
50. A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of claim 5.
51. A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of claim 10.